Altamira治疗学,在欧洲首脑会议上介绍新的MRNA交付平台,目标是防治非生殖性疾病。 Altamira Therapeutics to present new mRNA delivery platforms at European summit, aiming to target non-liver diseases.

以百慕大为基地的一家生物技术公司Altamira治疗学公司,将于2026年1月28日至29日出席第5次以MRNA为基础的欧洲治疗学峰会,展示其SemaPhore和CycloPhore的交付平台。 Altamira Therapeutics, a Bermuda-based biotech firm, will present at the 5th mRNA-Based Therapeutics Summit Europe on January 28–29, 2026, showcasing its SemaPhore and CycloPhore delivery platforms. 这些基于浸化物的系统以21-氨酸序列为基础,通过逃避肝脏清理和保护RNA不受降解,能够有针对性地向非肝脏组织提供mRNA和环状RNA。 These peptide-based systems, built on a 21-amino acid sequence, enable targeted delivery of mRNA and circular RNA to non-liver tissues by evading liver clearance and protecting RNA from degradation. 这些平台在包括KRAS驱动的癌症和风湿性关节炎在内的各种疾病的临床前期模型中表现出成功。 The platforms have shown success in preclinical models for diseases including KRAS-driven cancers and rheumatoid arthritis. Altamira的 xPhoreTM平台支持多种核酸类型,可供颁发许可证。 Altamira’s xPhore™ platform supports multiple nucleic acid types and is available for licensing. 该公司成立于2003年,总部设在百慕大汉密尔顿,在瑞士巴塞尔开展业务。 该公司告诫说,前瞻性声明涉及与发展、监管和金融稳定有关的风险。 The company, founded in 2003 and headquartered in Hamilton, Bermuda, with operations in Basel, Switzerland, cautioned that forward-looking statements involve risks related to development, regulation, and financial stability.